Condition
Advanced Solid Malignant Tumors
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Treatment Research
5 treatments under study, led by Ds1123
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
80.0%
-6.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
80% success
Data Visualizations
Phase Distribution
5Total
Phase 1 (5)
Trial Status
Completed4
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02675491Phase 1CompletedPrimary
Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors
NCT02690337Phase 1CompletedPrimary
Study of DS-1123a in Advanced Solid Tumours
NCT02192567Phase 1TerminatedPrimary
Open Label Study of DS-5573a
NCT00503711Phase 1CompletedPrimary
Phase I Chinese PK
NCT01290471Phase 1CompletedPrimary
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Showing all 5 trials
Research Network
Common Treatments
- Ds11231
- Ds6051b1
- U315651
- Vandetanib1
- Ds5573a1
Active Sponsors
- Daiichi Sankyo Co., Ltd.3
- Daiichi Sankyo1
- Genzyme, a Sanofi Company1
Top Investigators
National Cancer Center Hospital
Daiichi Sankyo
Related Conditions
- Advanced Ovarian Cancer1